Tuesday, November 12, 2024 9:56:20 AM
I will not stop posting positives about this company, as long as Aguilar delivers.
All you posted was pre-Aguilar.
The company is much different now, and is poised to capitalize and commercialize.
I noticed you haven't weighed in on all the new hires very much, and heavy involvement of other companies.
Aguilar, Gallegos, Bhatt, Zarling, University of AZ, Coastar, Stanford Medicine, Kawamura, Carlsbad, FDA, Gummies, Amazon, Joseph Jackson, Sowmya, Levitiracetam, Patent Attorney Furman, etc, etc.
This is not the old SOHM, if you don't have trust, that's on you.
I do agree with you about not roping in new eyes, all should be cautious in the OTC especially.
I understand the past history was largely undelivered.
Lunch and Learn in a week with Sohm, Coastar, Hygia, at LaJolla Institute.
I'm staying positive, but I respect your opinion greatly.
All you posted was pre-Aguilar.
The company is much different now, and is poised to capitalize and commercialize.
I noticed you haven't weighed in on all the new hires very much, and heavy involvement of other companies.
Aguilar, Gallegos, Bhatt, Zarling, University of AZ, Coastar, Stanford Medicine, Kawamura, Carlsbad, FDA, Gummies, Amazon, Joseph Jackson, Sowmya, Levitiracetam, Patent Attorney Furman, etc, etc.
This is not the old SOHM, if you don't have trust, that's on you.
I do agree with you about not roping in new eyes, all should be cautious in the OTC especially.
I understand the past history was largely undelivered.
Lunch and Learn in a week with Sohm, Coastar, Hygia, at LaJolla Institute.
I'm staying positive, but I respect your opinion greatly.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
